Acadia Pharmaceuticals | ACAD - Cash And Equivalent



Acadia Pharmaceuticals reported $762M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
ALKERMES USD 521.2M 121.39M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Corcept Therapeutics USD 102.74M 12.93M Jun/2025
Cytokinetics USD 74.94M 863.28M Jun/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Moderna USD 1.28B 344M Jun/2025
Neurocrine Biosciences USD 264M 69.9M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Prothena USD 371.44M 99.95M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025